Overview

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Status:
COMPLETED
Trial end date:
2023-05-05
Target enrollment:
Participant gender:
Summary
Primary objective * The tolerability and safety of SAR443809 Secondary * The PK parameters of SAR443809 * The PD activity of SAR443809 * The immunogenicity of SAR443809
Phase:
PHASE1
Details
Lead Sponsor:
Sanofi